Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  ALEXION PHARMACEUTICALS INC
 2. Date of Event Requiring Statement (Month/Day/Year)
06/19/2015		 3. Issuer Name and Ticker or Trading Symbol
SYNAGEVA BIOPHARMA CORP [GEVA]
(Last)
(First)
(Middle)
352 KNOTTER DRIVE, 		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

CHESHIRE, CT 06410		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common stock, par value $0.001 per share, of Synageva 21,021,124
I
Through direct, wholly owned subsidiary (see explanatory note)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ALEXION PHARMACEUTICALS INC
352 KNOTTER DRIVE
CHESHIRE, CT 06410		     X    
Pulsar Merger Sub Inc
(NOW ALEXION PHARMA LLC)
(SEE EXPLANATORY NOTE) 352 KNOTTER DRIVE
CHESHIRE, CT 06410		     X    

Signatures

/s/ Michael V. Greco, Alexion Pharmaceuticals, Inc., Vice President of Law and Corporate Secretary 06/29/2015
**Signature of Reporting Person Date
/s/ Michael V. Greco, Alexion Pharma LLC (as successor in interest to Pulsar Merger Sub Inc.), Sole Manager 06/29/2015
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 
Remarks:
This is a joint filing by Alexion Pharmaceuticals, Inc. ("Alexion") and Alexion Pharma LLC (as successor in interest to Pulsar Merger Sub Inc. ("Pulsar")), a direct, wholly owned subsidiary of Alexion.

As previously announced, at midnight at the end of June 19, 2015, the exchange offer of Pulsar for all of the outstanding shares of Synageva BioPharma Corp. ("Synageva") expired. Alexion accepted for exchange all 21,021,124 shares of Synageva common stock validly tendered into the exchange offer and not properly withdrawn as of the expiration of the offer.

Also as previously announced, on June 22, 2015, Alexion acquired all of the remaining shares of outstanding Synageva common stock through the merger of Pulsar with and into Synageva, with Synageva surviving the merger.

Immediately following that merger, the corporation surviving that merger merged with and into Galaxy Merger Sub LLC, with Galaxy Merger Sub LLC surviving the merger and renamed "Alexion Pharma LLC."

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.